Global Blood Therapeutics
181 Oyster Point Blvd
South San Francisco
California
94080
United States
Website: http://www.gbt.com/
Email: info@gbt.com
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
170 articles with Global Blood Therapeutics
-
GBT and Sickle Cell Disease Association of America to Host 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference
9/9/2020
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 15.
-
GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta® (voxelotor) in Six Middle Eastern Countries
9/8/2020
More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates
-
GBT Announces New Employment Inducement Grants - Sep 04, 2020
9/4/2020
Global Blood Therapeutics, Inc. announced that on September 1, 2020, the compensation committee of GBT’s board of directors granted seven new employees options to purchase an aggregate of 11,678 shares of the company’s common stock with a per share exercise price of $60.45 and restricted stock units for an aggregate of 46,585 shares of the company’s common stock.
-
GBT Announces Participation in Upcoming Investor Conferences - Sep 03, 2020
9/3/2020
Global Blood Therapeutics, Inc. announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences
-
GBT Announces New Employment Inducement Grants - Aug 07, 2020
8/7/2020
Global Blood Therapeutics, Inc. announced that on August 1, 2020, the compensation committee of GBT’s board of directors granted seven new employees options to purchase an aggregate of 9,750 shares of the company’s common stock with a per share exercise price of $67.48 and restricted stock units for an aggregate of 55,675 shares of the company’s common stock.
-
GBT Reports Recent Business Progress and Second Quarter 2020 Financial Results
8/5/2020
Announced plans to seek approval of Oxbryta for younger pediatric patients in the United States and seek approval of Oxbryta in Europe
-
GBT Announces Participation in Upcoming Investor Conferences
7/30/2020
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences: William Blair Biotech Focus Conference 2020 on August 6 at 3:00 p.m. ET; Wedbush PacGrow Healthcare Virtual Conference on August 11 at 2:55 p.m. ET; and Canaccord Genuity 40 th Annual Growth Virtual Conference on August 13 at 1:30
-
GBT to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
7/29/2020
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2020 financial results on Wednesday, August 5, 2020, after U.S. financial markets close. Management will host a conference call on Wednesday, August 5, 2020, at 4:30 p.m. ET to provide a general business update and to discuss second quarter 2020 financial results. To participate in the conference call, please dial 877-407-3982 (
-
GBT Announces New Employment Inducement Grants - July 08, 2020
7/8/2020
Global Blood Therapeutics, Inc. announced that on July 1, 2020, the compensation committee of GBT’s board of directors granted 11 new employees restricted stock units for an aggregate of 27,550 shares of the company’s common stock.
-
GBT Awards $250,000 in ACCEL Grants to Advance Access to Care for People Living with Sickle Cell Disease
6/25/2020
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five U.S. nonprofit organizations serving the sickle cell disease (SCD) community have been awarded a total of $250,000 through the company’s 2020 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program.
-
GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe
6/24/2020
Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease Marketing Authorization Application submission planned by mid-2021 SOUTH SAN FRANCISCO, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Oxbryta ® (voxelotor) tablets to treat hemolytic anemia in sickle cell dis
-
GBT Announces Plans to Seek Expanded Labeling for Oxbryta® (voxelotor) to Treat Children Ages 4 to 11 Years with Sickle Cell Disease
6/8/2020
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced plans to expand the potential use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in children ages 4 to 11 years, following a Type B meeting with the U.S. Food and Drug Administration (FDA).
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
GBT Announces New Employment Inducement Grants - June 03, 2020
6/3/2020
Global Blood Therapeutics, Inc. announced that on June 1, 2020, the compensation committee of GBT’s board of directors granted seven new employees restricted stock units for an aggregate of 34,000 shares of the company’s common stock.
-
GBT Announces Participation at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
6/2/2020
Global Blood Therapeutics, Inc. announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast on Tuesday, June 9, 2020, at 3:50 p.m. Eastern Time.
-
GBT Announces Upcoming Data Presentations During Virtual Edition of 25th Annual European Hematology Association Congress
5/14/2020
Data include retrospective analysis of landmark STOP 2 Study highlighting correlation between higher hemoglobin levels and lower transcranial Doppler (TCD) flow velocities in children with sickle cell disease SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts will be presented during the virtual edition of the 25 th Annual European Hematology Association (EHA) Congress taking place June 11-1
-
GBT Announces New Employment Inducement Grants - May 07, 2020
5/7/2020
Global Blood Therapeutics, Inc. announced that on May 1, 2020, the compensation committee of GBT’s board of directors granted seven new employees restricted stock units for an aggregate of 36,500 shares of the company’s common stock.
-
GBT Reports Recent Business Progress and First Quarter 2020 Financial Results
5/6/2020
Global Blood Therapeutics, Inc. reported recent business progress and financial results for the first quarter ended March 31, 2020.
-
GBT to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020
4/29/2020
Global Blood Therapeutics, Inc. announced that it will report first quarter 2020 financial results on Wednesday, May 6, 2020, after U.S. financial markets close..
-
GBT Announces New Employment Inducement Grants - April 03, 2020
4/3/2020
Global Blood Therapeutics, Inc. announced that on April 1, 2020, the compensation committee of GBT’s board of directors granted three new employees restricted stock units for an aggregate of 10,550 shares of the company’s common stock.